NYSE:WATLife Sciences
Waters (WAT) Valuation Check After Q1 Beat And Higher 2026 Guidance
Waters (WAT) is back in focus after first quarter 2026 results beat expectations, aided by strong organic growth and the BD Biosciences and Diagnostic Solutions acquisitions, alongside higher full year 2026 financial guidance.
See our latest analysis for Waters.
Investors have responded quickly to the upgraded 2026 guidance, with the stock delivering a 17.64% 7 day share price return and an 8.60% 90 day share price return. However, year to date the share price return is down 7.02%, while the...